• Progress towards zero environmental impact
  • Being respected for adding value to society
  • Ensure distinct core capabilities and evolve culture

  • Further raise the innovation-bar for diabetes treatment
  • Develop a leading portfolio of superior treatment solutions for obesity
  • Strengthen and progress the Rare disease pipeline 
  • Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD

  • Strengthen Diabetes leadership - aim at global value market share of more than 1/3
  • More than 25 billion DKK in Obesity sales by 2025
  • Secure a sustained growth outlook for Rare disease

  • Deliver solid sales and operating profit growth:
    • Deliver 6-10% sales growth in International Operations
    • Transform 70% of sales in the USA1
  • Drive operational efficiencies across the value chain to enable investments in future growth assets
  • Deliver free cash flow to enable attractive capital allocation to shareholders



1. From 2015 to 2022, 70% of sales to come from products launched from 2015


The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.